Lab services provider Barc Lab has entered into a global strategic alliance with OWL Metabolomics to bring metabolomics technology to clinical trials.

The combination of Barc’s central lab services with OWL’s metabolomics technology is expected to aid biopharmaceutical companies engaged in non-alcoholic steatohepatitis (NASH) research.

OWL Metabolomics noted that the alliance will support drug research and help in obtaining better insights into the biological impact of their compounds.

The company’s technology enables the discovery of more than 1,000 small metabolites from a single sample. This is intended for thorough evaluation of the disease complexity by analysing metabolic alterations.

Barc Lab CEO Mario Papillon said: “OWL is known for their strength in the metabolomics field, particularly in liver disease, and offers valuable insight into biological systems.

“This collaboration will allow us to provide our customers with the solutions they need to develop tailored treatments for NASH patients and address this desperate unmet medical need.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Barc Lab provides central lab services for testing across different fields such as oncology, immunology, genetics, microbiology and clinical pathology.

OWL Metabolomics CEO Pablo Ortiz said: “We are confident that the two companies together will bring a very positive impact to the important field of NASH research and become valued reference service providers for clinical trials in liver disease research.”

This company is focused on offering metabolomics services that will support clinical trials in liver diseases and other human disorders.